These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1342 related articles for article (PubMed ID: 26885860)

  • 21. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.
    Neeson P; Shin A; Tainton KM; Guru P; Prince HM; Harrison SJ; Peinert S; Smyth MJ; Trapani JA; Kershaw MH; Darcy PK; Ritchie DS
    Gene Ther; 2010 Sep; 17(9):1105-16. PubMed ID: 20428216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
    Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
    J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
    Boroughs AC; Larson RC; Marjanovic ND; Gosik K; Castano AP; Porter CBM; Lorrey SJ; Ashenberg O; Jerby L; Hofree M; Smith-Rosario G; Morris R; Gould J; Riley LS; Berger TR; Riesenfeld SJ; Rozenblatt-Rosen O; Choi BD; Regev A; Maus MV
    Mol Ther; 2020 Dec; 28(12):2577-2592. PubMed ID: 32755564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
    Cheuk AT; Mufti GJ; Guinn BA
    Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
    Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
    J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
    Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA
    Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The signaling and the metabolic differences of various CAR T cell designs.
    Razavi AS; Loskog A; Razi S; Rezaei N
    Int Immunopharmacol; 2023 Jan; 114():109593. PubMed ID: 36700773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 31. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
    Chen F; Fan C; Gu X; Zhang H; Liu Q; Gao X; Lu J; He B; Lai X
    Med Sci Monit; 2015 Jul; 21():2110-5. PubMed ID: 26195067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
    Zhukovsky EA; Morse RJ; Maus MV
    Curr Opin Immunol; 2016 Jun; 40():24-35. PubMed ID: 26963133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.
    Cartellieri M; Bachmann M; Feldmann A; Bippes C; Stamova S; Wehner R; Temme A; Schmitz M
    J Biomed Biotechnol; 2010; 2010():956304. PubMed ID: 20467460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
    Maher J; Brentjens RJ; Gunset G; Rivière I; Sadelain M
    Nat Biotechnol; 2002 Jan; 20(1):70-5. PubMed ID: 11753365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.
    Hombach AA; Chmielewski M; Rappl G; Abken H
    Hum Gene Ther; 2013 Mar; 24(3):259-69. PubMed ID: 23350854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic modification of T cells for cancer therapy.
    Imai C; Campana D
    J Biol Regul Homeost Agents; 2004; 18(1):62-71. PubMed ID: 15323362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.